Publicaciones en colaboración con investigadores/as de Aarhus University Hospital (19)

2022

  1. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

    Osteoporosis International, Vol. 33, Núm. 12, pp. 2527-2536

2019

  1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  2. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

2018

  1. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371

  2. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

2017

  1. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

  2. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594

2016

  1. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks

    Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878

  2. Effets du tériparatide et du risédronate sur la DMO et la consolidation fracturaire chez des patients âgés avec fracture pertrochantérique récente: Résultats finaux d'un essai clinique randomisé de 78 semaines

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A83-A84

  3. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

    Calcified Tissue International, Vol. 99, Núm. 3, pp. 259-271

  4. Fracture rate, back pain and quality of life in patients with osteoporosis treated with teriparatide: Results of the European observational study ExFOS (Extended Forsteo® Observational Study)

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A188-A189

2013

  1. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: The European Forsteo Observational Study

    BMC Musculoskeletal Disorders, Vol. 14

2012

  1. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-Year results from the EFOS study

    Journal of Rheumatology, Vol. 39, Núm. 3, pp. 600-609

  2. Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)

    Calcified Tissue International, Vol. 90, Núm. 5, pp. 373-383

  3. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

    European Journal of Endocrinology, Vol. 166, Núm. 1, pp. 87-97

2011

  1. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

    Osteoporosis International, Vol. 22, Núm. 10, pp. 2709-2719

2009

  1. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)

    Calcified Tissue International, Vol. 85, Núm. 6, pp. 484-493

  2. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: An analysis by gender and menopausal status

    Osteoporosis International, Vol. 20, Núm. 12, pp. 2095-2104

2008

  1. Characterization of patients in the European Forsteo Observational Study (EFOS): Postmenopausal women entering teriparatide treatment in a community setting

    Current Medical Research and Opinion, Vol. 24, Núm. 2, pp. 377-384